MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022
By HospiMedica International staff writers Posted on 15 Nov 2022 |
MP Biomedicals (Eschwege, Germany) is exhibiting its wide product portfolio of POC, screening and confirmatory tests, backed by a range of testing methods that aid in the diagnosis, detection, and recovery from diseases, at MEDICA 2022.
At this year’s edition of MEDICA, MP Biomedicals is exhibiting the AutoBlot System 36, an intelligent Western Blot processor that enables automated washing and incubation of up to 36 assay strips per run at a pre-selected temperature. The AutoBlot System 36 helps to satisfy Immunoblot needs by minimizing human error, increasing productivity and delivering accurate and consistent results. MP Biomedicals is also showcasing its innovative diagnostic tests such as the Rapid SARS-CoV-2 Antigen Test Card, an IVD test for private use to detect SARS-CoV-2 antigens from anterior nasal swabs, alongside the Rapid 2019-nCoV IgG/IgM Combo Test Card, which is an immunochromatography based one-step in vitro test designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV,SARS-CoV-2) in human serum, plasma, or whole blood.
MP Biomedicals is also highlighting its POC testing and screening solutions for the qualitative assessment of drugs and their metabolites in human urine and saliva. Visitors to the MP Biomedicals booth at MEDICA 2022 can gain insights into the MP Diagnostics HIV BLOT 2.2 qualitative enzyme immunoassay for the in vitro detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) in human serum or plasma. HIV BLOT 2.2 is intended for use as a more specific supplemental test on human serum or plasma specimens found repeatedly reactive using screening procedures such as the Enzyme-Linked Immunosorbent Assay (ELISA). Also on display at the event is the MP Diagnostics MULTISURE HIV 1/2 Confirmatory Test for use as a rapid confirmatory test to detect and differentiate antibodies specific to HIV-1 gp120, HIV-1 gp41, HIV-1 p24 and HIV-2 gp36, HIV-2 gp105 antigens in human serum or plasma.
Related Links:
MP Biomedicals
Latest MEDICA 2022 News
- Fisher & Paykel Highlights Innovative Products for Respiratory Care at MEDICA 2022
- Huntleigh Exhibits Range of Vital Signs Monitoring Solutions at MEDICA 2022
- Owen Mumford Presents Cutting-Edge Capillary Blood Sampling Devices for POC Testing
- Noul Demonstrates AI-Driven On-Site Diagnostics Platform at MEDICA 2022
- KUKA Presents Robot-Based Assistance Systems at MEDICA 2022
- Heyer Medical Exhibits State-Of-The-Art Ventilators, Anesthesia Workstations and Surgical Lights
- Progetti Highlights Advanced Defibrillators for Emergency Medicine at MEDICA 2022
- LG Electronics Showcases State-Of-The-Art Surgical, Diagnostic and Clinical Monitors at MEDICA 2022
- World’s First Detachable 4K 8MP Handheld Camera for Telemedicine Showcased at MEDICA 2022
- EIZO Exhibits Complete New CuratOR Series of Surgical Monitors at MEDICA 2022
- Parker Labs Showcases Range of Ultrasound Equipment Cleaners and Disinfectants
- OptoMedic Demonstrates Range of Endoscopic Imaging Systems at MEDICA 2022